Winning the
RACE
For precision medicine.
June 2022 NASDAQ:IPA
Disclosures
Disclaimer
This presentation is not, & nothing in it should be construed as, an offer, invitation or recommendation in respect of ImmunoPrecise Antibodies Ltd. (the "Company") securities, or an offer, invitation or recommendation to sell, or solicitation of an offer to buy, the facilities or of the Company's securities in any jurisdiction. Neither this presentation nor anything in it shall form the basis of any contract or commitment. This presentation is not intended to be relied upon as advice to investors or potential investors & does not take into account the investment objectives, financial situation or needs of any investor. All investors should consider such factors in consultation with a professional advisor of their choosing when deciding if an investment is appropriate. The Company has prepared this presentation based on information available to it, including information derived from public sources that have not been independently verified. No representation or warranty, express or implied, is provided in relation to the fairness, accuracy, correctness, completeness or reliability of the information, opinions or conclusions expressed herein. These projections should not be considered a representation of the Company's potential cash generation performance in any way.
Forward Looking Statements
This presentation includes forward-looking statements, including future-oriented financial information ("FOFI"). Forward-looking statements can generally be identified by the use of language such as "may", "expect", "estimate", "anticipate", "intend", "believe", "potential" & "continue" or the negative thereof or similar variations. Forward- looking statements are not statements of historical fact or assurances of future performance. They are based on the current beliefs, expectations & assumptions of the Company's management about the Company's business, planned acquisitions, future plans, anticipated events & other future conditions. All forward-looking statements attributable to the Company or persons acting on its behalf apply only as of the date of this document & are expressly qualified in their entirety by the cautionary statements included in this presentation. The Company undertakes no obligation to update or revise these forward-looking statements to reflect events or circumstances that arise after the date made or to reflect the occurrence of unanticipated events. Inevitably, some assumptions will not materialize, & anticipated events & circumstances may affect the ultimate financial results. Projections are inherently subject to substantial & numerous uncertainties & to a wide variety of significant business, economic & competitive risks, & the assumptions underlying the projections may be inaccurate in any material respect, including, but not limited to, those risks set forth in the Company's Management Discussion & Analysis for the year ended April 30, 2021, a copy of which may be obtained from SEDAR.com. The purpose of FOFI provided in this presentation is to provide prospective investors with information pertaining to the Company's long-term business objectives. Readers are cautioned that this information may not be appropriate for other purposes.
2
The Opportunity
The HUB of Biotherapeutic Intelligence
A hybrid of platforms and technologies in the SCIENCE and BUSINESS of therapeutic discovery.
LENSai
Engineered for the scientific race | A new lens on | Natural | Engineered for the clinical race | |||||
Antibody research & development | biotherapeutic | Artificial | Licensing | |||||
Protein manufacturing | intelligence: | Complex | Partnership | |||||
BioStrand
©2022 IPA. All rights reserved. CONFIDENTIAL | Engineered for the race and the shared pursuit of clinical success. | 3 |
The Problem
Matching the mutation to the therapy
THE PROBLEM
The Problem
Matching the mutation to the therapy - need for rapid and accurate solutions for personalized medicine
The central challenges of | From sequence ... to therapy. |
computational biology are to: |
- Analyze massive multi-omic datasets to determine sequence and structural basis of disease, identify targets
- Rapidly analyze structural target data
to inform the design of safe and efficacious therapies - Accurately match individualized therapies to patients based on structural and functional characteristics of target
©2022 IPA. All rights reserved. CONFIDENTIAL | 5 |
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original Link
- Original Document
- Permalink
Disclaimer
ImmunoPrecise Antibodies Ltd. published this content on 27 May 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 May 2022 12:02:14 UTC.